If you feel like depressing yourself today, check out this blog post from Derek Lowe at In the Pipeline. Lowe points to an analysis performed on a clinical trial for gabapentin (marketed by Pfizer under the name Neurontin) in the '90s. "The authors find, by analyzing a large trove of documents released during lawsuit discovery proceedings, that [the clinical trial] was not really intended to be a clinical trial. Instead, it was a marketing program," Lowe writes. The study seems to have been unblinded and uncontrolled, he notes, adding: "This is an extremely foul technique, which brings the companies who use it, the entire drug industry, and the whole idea of clinical research into disrepute."
'An Extremely Foul Technique'
Jul 01, 2011